Login to Your Account

Medivir Gets $45M for North American Royalties on Xerese

By Cormac Sheridan

Thursday, June 30, 2011
Adopting the old adage that a bird in the hand is worth two in the bush, Medivir AB is forgoing a future revenue stream from North American sales of its cold sore product Xerese in return for an immediate payment of $45 million from its partner Meda AB.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription